Amneal Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Amneal Pharmaceuticals (AMRX).

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

8Buy

Consensus RatingBuy# Analysts8Avg. Consensus PT$18Upside to Avg. PT-13.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 22, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$22→$24
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$27
Sep 17, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$16→$20
Sep 9, 2026	Leerink Partners	Daniel Clark	Initiate	Outperform	$23
Aug 26, 2026	JP Morgan	Chris Schott	Reinstates	Overweight	$22
Aug 3, 2026	UBS	Ashwani Verma	PT Raise	Buy	$23→$25
Jul 15, 2026	UBS	Ashwani Verma	PT Raise	Buy	$19→$23
May 20, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$15→$16
Apr 17, 2026	UBS	Ashwani Verma	Initiate	Buy	$19
Mar 2, 2026	Truist Securities	Les Sulewski	PT Raise	Buy	$15→$17
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$15
Oct 31, 2025	Piper Sandler	David Amsellem	PT Raise	Overweight	$11→$13
Sep 16, 2025	JP Morgan	Chris Schott	PT Raise	Overweight	$12→$14
Mar 3, 2025	Barclays	Balaji Prasad	PT Raise	Overweight	$10→$11
Feb 24, 2025	JP Morgan	Chris Schott	Upgrade	Neutral→Overweight	$9→$12
Nov 11, 2024	Piper Sandler	David Amsellem	PT Raise	Overweight	$9→$11
Oct 2, 2024	Truist Securities	Les Sulewski	PT Raise	Buy	$10→$12
Sep 6, 2024	JP Morgan	Chris Schott	Upgrade	Underweight→Neutral	$9
Aug 13, 2024	Barclays	Balaji Prasad	PT Raise	Overweight	$8→$10
Aug 12, 2024	Truist Securities	Les Sulewski	PT Raise	Buy	$9→$10

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24

JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $22 to $24.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27

Oppenheimer analyst Les Sulewski initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $27.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $16 to $20.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23

Leerink Partners analyst Daniel Clark initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $23.

Benzinga Newsdesk

PRO
JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target

JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25

UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $23 to $25.

Benzinga Newsdesk

Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24

PRO
Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27

PRO
Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

PRO
Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23

PRO
JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target

PRO
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25

People Also Watch

People Also Watch

Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24

PROOppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27

PROBarclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

PROLeerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23

PROJP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target

PROUBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24

PRO
Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27

PRO
Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

PRO
Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23

PRO
JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target

PRO
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25